Drug Profile
Tadalafil orally-dissolving film - NAL Pharma
Alternative Names: NAL8233; Tadalafil ODF - NAL PharmaLatest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Gastrokinetics; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Pyridones; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Erectile dysfunction
Highest Development Phases
- Clinical Phase Unknown Erectile dysfunction
Most Recent Events
- 26 May 2022 Tadalafil orally-dissolving film is still in clinical trials for erectile dysfunction in Hong Kong (NAL Pharma pipeline, May 2022)
- 28 Apr 2019 No recent reports of development identified for clinical-Phase-Unknown development in Erectile-dysfunction in Hong Kong (Sublingual, Film)
- 23 Mar 2016 Tadalafil orally-dissolving film is available for licensing in World as of 23 Mar 2016. http://www.nalpharma.com/index.php?lang=en